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Abstract
Whereas adverse effects induced by xenobiotics are mainly linked to the pharmacological
effect, the adverse side-effects induced by biological agents (BA) are often target-related and
linked to the biological consequences of their action. Based on these differences, an original
classification of the adverse effects has been proposed. Five types of adverse effects induced by
BA are described (α, β, γ, δ, and ε). This classification provides a very useful scheme for a better
understanding of these adverse effects. This approach should help to better characterize the
pathogenic mechanisms involved and to optimize their management. Healthcare professionals
should be aware of the specific risks related to this relatively new class of drugs. Close
monitoring of these BA is therefore recommended.
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258 F. Aubin et al.1. Introduction
For about 10 years, biological agents (BA), including cytokines,
monoclonal antibodies and fusion proteins are widely used in
various autoinflammatory and immune diseases and tumours.
Besides, they may induce new side-effects that require
specific knowledges as they differ from common side-effects
induced by conventional drugs.
Although very heterogeneous, adverse side-effects in-
duced by traditional drugs may be classified into 5 types.1,2
Type A reactions are the most frequent and correspond to
the pharmacological activity of the drug. They are thus
predictable. Type B reactions are immune-mediated and
are thus not predictable. They include immediate and
delayed hypersensitivity reactions. Type C and D reactions
involve short-term and long-term toxicities. They are linked
to the chemical structure of the drug and its metabolism
(i.e., hepato- and nephrotoxicity). Type E reactions occur
after withdrawal of the drug.
In contrast, BA demonstrate clear differences with tradi-
tional drugs in terms of chemistry, mode of action, metabolism
and immunogenicity (Table 1). Contrary to traditional chem-
ically synthetized drugs, BA are large protein complexes, which
can be obtained from cultures of bacteria, yeast, insects,
plants, or mammalian cells engineered with the gene of
interest or can be purified from natural sources (i.e. clotting
factors). Manufacturing quality is a significant issue relative
to the toxicity of BA. The development of recombinant tech-
nology represented the single biggest advance leading to
humanized products with minimal or no contaminants in
comparison to products purified from animal tissues. Never-
theless, the type of manufacturing process including choice of
cell type, culture medium, and purification method can result
in changes to the protein.Table 1 Comparison of traditional drugs and biological agents
(6,37): MW: molecular weight.
Traditional drugs Biological agents
Small molecule
(MWb1 kDa)
Synthetized chemicals
(xenobiotics)
Large complex molecules
(MWNN1 kDa)
Structurally similar to autologous
proteins
Produced with molecular genetic
technique and purified from
engineered cells
Stable
Well characterized and
homogeneous
Metabolized to active
and inactive products
Heat sensitive
Heterogeneous composition
Digested and processed, not
metabolized
Catabolized to endogenous amino
acids
Cytochrome P450
involvement
Multiple drug
interactions
Oral administration
possible
Linear dose–response
Pharmacological effect
Cytochrom P450 independent
No drug interactions
Oral administration not possible
Non linear dose–response
Biological effectBecause of their structure (large molecules) and origin
(foreign non-self proteins), BA are intrinsically immunogenic,
and may induce anti drug antibodies, which may be related to
drug reactions at one hand3 and reduced efficacy at the other
hand.4
Whereas adverse side-effects induced by xenobiotics are
mainly linked to the pharmacological effect, the adverse
side-effects induced by BA are often target-related and
linked to the biological consequences of their action.5 Based
on these differences, Pichler6 proposed an original classifi-
cation of the adverse side-effects induced by BA. As for
xenobiotics, adverse drug reactions of BA are classified by
their pathomechanism. Five types of adverse side-effects
were described (Table 2). Types α,β,γ,and δ reactions may
be also related to different aspects of the immunotoxicity
induced by BA, including immunostimulation, immunode-
viation (immunosuppression and autoimmunity), immunoge-
nicity (hypersensitivity reactions), cross-reactivity and other
non-immunological adverse effects.7,8
Type α reactions are induced by high cytokine levels. The
cytokine release syndrome observed during IFN or IL-2
treatment includes fever, asthenia, arthragia, headache,
myalgia, gastrointestinal symptoms (nausea, vomiting, diar-
rhoea). Cutaneous eruption mimicking a Sweet's syndrome or
acute febrile neutrophilic dermatosis (Fig. 1) has also been
described after administration of granulocyte colony stimu-
lating factor that causes increased neutrophil proliferation
and differentiation.9 The term cytokine storm have been
used to describe a multi-organ dysfunction syndrome
induced by an inappropriate generalized inflammatory
response.10 The release of high levels of pro-inflammatory
cytokines including IL-1b, TNF-a, IFN-a/b/g, IL-6 and IL-8,
and complement activation are considered to be the main
underlying mechanisms.7
Type β reactions involve hypersensitivity reaction linked to
the immunogenicity of BA. Although mouse and chimaeric
antibodies are more immunogenic, humanized and fully
human antibodies can still elicit an anti-idiotypic immune
response.11 Development of antibodies to BA or anti-drug
antibodies (ADA) depends on several factors including the
immunogenicity of the protein (mouse vs human), the route of
administration (subcutaneous versus intravenous), treatment
regimens (intermittent versus continuous), and the concom-
itant use of immunosuppressive drugs.12 ADA development is
associated with decreased therapeutic effectiveness and, in
many cases, with the occurrence of immunoallergic adverse
events. However, there is no clear evidence that ATIs have anTable 2 Classification of adverse side-effects of biological
agents (6).
Type
α
Reactions related to cytokine and cytokine released
syndrome.
Type
β
Reactions include both immediate and delayed
hypersensitivity reactions.
Type
γ
Reactions are related to immune imbalance
syndrome.
Type
δ
Cross-reactions related to the expression of the same
antigen on different tissue.
Type
ε
Reactions are non-imunological side-effects (new and
original unexpected functions of biological agent)
Figure 1 Sweet's syndrome or acute febrile neutrophilic derma-
tosis after the administration of filgrastim (type α reaction).
259The complexity of adverse side-effects to biological agentsimpact on efficacy or safety, nor a need tomeasure or prevent
them in clinical practice.13
Both immediate and delayed-type reactions may occur.14
Immediate reactions occur in 3–5% of patients treated with
chimaeric BA. They often occur at the site of sub cutaneous
injection (Fig. 2) leading to a local flare and wheal reaction.
Such reactions can disappear when the treatment is
continued, which suggests that tolerance may be induced.
These reactions are not dose-dependent, they can relapse at
prior injection sites (recall phenomenon). Local reactions are
mostly not IgE-mediated and may involve non-immunologic
irritation to BA or to its excipients.14
Acute systemic reaction with fever, urticaria and
anaphylaxis may also occur, i.e. during infliximab, rituximab,
omalizumab or natalizumab infusions. These reactions
commonly/usually appear rapidly within minutes and last
for 30 to 60 min. No correlation between the atopic status
of the patient and the incidence of hypersensitivity
reactions has been demonstrated with different TNF-alpha
blocking agents.15
The majority are mild reactions and can be reduced by
slowing the infusion rate and giving antihistamines and
paracetamol. More severe systemic reaction may requireFigure 2 Local reaction (type β) after etanercept subcuta-
neous injection.corticosteroids.14,16 Although premedication is often rou-
tinely given before infusion consisting of paracetamol,
antihistamines and/or corticosteroids, there are no solid
evidence that prophylactic medication can prevent infusion
reactions.12,14 Desensitization protocols have also been
proposed.17
The pathomechanisms of infusion reactions remain unclear.
The immunogenicity of BA along with the formation of ADA, the
release of high level of pro-inflammatory cytokines or histamine
and complement activation have been suggested. Although the
formation of ADA may be reduced by the concomitant use of
immunosuppressive drugs,12,18 there is no clear evidence for
prevention in clinical practice.3,13
Delayed reactions occur N6 h after treatment and are
immunoglobulin-mediated. Formation of IgG antibodies against
the BA may occur rather frequently, up to 68% of patients
treated with the chimaeric antibody infliximab.19 However,
these antibodies anti-BA are not systematically associated with
symptoms and the most frequent consequence is inactivation
of the BA and reduction of efficacy.20 Formation of antibodies
may induce the activation of complement cascade through
immune complexes formation resulting in serum sickness,
vasculitis (Fig. 3) and nephritis.21 The sensitization and
antibodies formation to anti-TNF agents can be reduced by
the co-medication with methotrexate.12,19
Type γ reactions are related to immunodeviation,
including immunosuppression and autoimmunity through
immune or cytokine imbalance. Tests to detect hypersensi-
tivities like skin tests or in vitro detection of antibodies are
negative. BA may induce an immunodeficiency which is
beneficial for the disease but deleterious for the optimal and
rapid control of infection or tumoral cells. Anti-TNF-α agents
are very effective for psoriasis rheumatoid arthritis, anky-
losing spondylitis and Crohn's disease but may be associated
with severe infections such as herpes zoster,22 tuberculosis
or listeriosis. The monoclonal antibodies natalizumab,
efalizumab, and rituximab (used for the treatment of
multiple sclerosis, psoriasis, haematological malignancies,
Crohn's disease, and rheumatic diseases) have been associated
with progressive multifocal leukoencephalopathy caused by
reactivation of the polyomavirus JC.23
In addition to the infectious risk, the delayed risk of
cancer is still an important issue and may be related to the
immunodeficiency induced by BA. However, many biological
agents have also proved their efficiency in various tumours
as their direct and targeted effects makes them superior to
conventional cytotoxic drugs. Immunosuppression with TNF
inhibition increases the risk for certain malignancies,24–26Figure 3 Cutaneous vasculitis (type β) during adalimumab
treatment in Crohn's disease.
260 F. Aubin et al.including lymphoma and non-melanoma skin cancer, but
data for actual rates, however, are confounded by past or
concomitant use of immunosuppressive agents.27–29 In a
recent meta-analysis assessing the risk of lymphoma in 8905
Crohn's disease patients treated with anti-TNF agents and
immunosuppressive drugs, Segel et al.30 observed a signif-
icant increase of standardized incidence ratio in these
patients when compared with the expected rate derived
from the Surveillance, Epidemiology, and End Results
database. However, this increase was not significantly
different from those observed in patients receiving immu-
nosuppressive drugs alone. In a meta-analysis including 5356
patients with Crohn's disease, anti-TNF therapy did not
increase the risk of death, malignancy, or serious infec-
tion.31 However, the follow-up was not more than one year.
Altogether, these different studies suggest that although the
risk of cancer associated with chronic use of anti-TNF
therapy as sole therapy has not been assessed, the
risk-to-benefit profile of the TNF-alpha inhibitors in adult
patients appears to be favorable.32 Larger, long-term
studies with appropriate control groups will be necessary
to fully assess the risk of cancer.
BA may also unmask a pre-existing or cause an cytokine
imbalance resulting in autoimmunity and auto-inflammatory
syndrome. Lupus-like syndrome, systemic sclerosis, thyroid-
itis, hepatitis nephritis, Guillain-Barré syndrome, and alopecia
areata have been reported with anti-TNF-a agents.21,33
Paradoxical adverse side-effects have been reported with
TNF antagonists. They correspond to the occurrence during
anti-TNF treatment of an unexpected pathological condition
that usually responds well to this therapeutic class of drug.
Paradoxical psoriasis-like eruptions (Fig. 4),34 vasculitis, and
even colitis35 have been described and linked to an increased
production of IFN-a36 and an increase of Th17 function alongFigure 4 Paradoxical psoriasiform eruption (type γ) during
adalimumab treatment in rheumatoid arthritis.with a reduction of regulatory T cells.37,38 Autoinflammatory
or allergic disease (atopic dermatitis) has been described with
anti-TNF-a39,40 suggesting a shift of the Th1-Th2 balance and
an increase of IL-17 production.41 The inhibition of suppressive
function of activated CTLA-4+ T cells by ipilimumab may also
lead to autoimmunity and autoinflammatory colitis.42
Type δ cross-reactions are related to the co-expression of
the target antigen on both pathologic and normal tissues.
Inhibitors of epidermal growth factor receptor (EGFR) are
used to treat various tumours and induce acneiform
eruptions (Fig. 5).43 Indeed, EGFR is expressed by various
carcinoma and is also involved in cutaneous homeostasis.
Type ε reactions are related to new and unexpected
physiological functions of BA revealed by the in vivo use in
humans. Neuropsychiatric adverse effects of IFN-a44,45 and
aggravation of heart failure by anti-TNF-a agents46 may
represent such type ε reactions.
The use of BA as a new alternative treatment for chronic
autoinflammatory and immune diseases and cancer is
expanding worldwide and new adverse side-effects are
becoming increasingly recognized. However, these BA are
so beneficial that adverse effects should not prevent their
use. The classification in 5 types proposed by Pichler6 and
discussed by Descotes and Gouraud7 provides a very useful
scheme for a better understanding of these adverse effects
(Table 3). This approach should help to better characterizeFigure 5 Acneiform eruption (type δ reaction) during cetuximab
treatment in head and neck.
Table 3 Classification of the main adverse effects induced
by themost common biological agents used for inflammatory
Bowel disease.
Biological
agent
Adverse effect Classification
Anti-TNF
Infliximab
Adalimumab
Certolizumab
Acute HSR (local and systemic)
Delayed HSR (serum sickness
disease)
Infection
Paradoxical adverse effects:
vasculitis, colitis,
psoriasis-like eruption, etc.…
Autoimmunity: lupus, hepati-
tis, thyroiditis, etc..
Heart failure
Type beta
reaction
Type gamma
reaction
Type gamma
reaction
Type gamma
reaction
Type epsilon
reaction
Anti- alpha-4
integrin
Natalizumab
Acute HSR (local and systemic)
Delayed HSR (serum sickness
disease)
Infection: progressive
multifocal
leukoencephalopathy
Autoimmunity: hepatitis,
thyroiditis
Type beta
reaction
Type gamma
reaction
Type gamma
reaction
Anti-IL12/
anti-IL23
Ustekinumab
Delayed HSR (serum sickness
disease)
Infection
Type beta
reaction
Type gamma
reaction
261The complexity of adverse side-effects to biological agentsthe pathogenic mechanisms involved and to optimize their
management.47 However, the relevance of this classification
needs to be evaluated in the daily care of patients. Besides
the development of pharmacogenomics48 will contribute to
predict not only the efficacy but also the safety of BA.
Healthcare professionals should be aware of the specific
risks related to this relatively new class of drugs. This also
underlines the importance of pharmacovigilance agencies
and registries in collecting these adverse events. Since 1995,
23% of BA approved have had at least one safety-related
regulated action and 11% have received a black-box warning.49
Close monitoring of these BA is therefore recommended.
2. Conflict of interest
None declared.
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